MedTrace Logo

Pemetrexed and Cisplatin Treatment Before Surgery in Non Small Cell Lung Cancer

NCT00259285 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2009-06-02

Study results available
· View outcomes & findings →

Summary

To determine the response to this regimen for therapy prior surgery in patients with locally advanced disease or metastatic disease.

Conditions

  • Non-Small-Cell Lung Cancer

Interventions

DRUG

pemetrexed

500 mg/m2, intravenous (IV), every 21 days x 3 cycles

DRUG

cisplatin

75 mg/m2, intravenous (IV), every 21 days x 3 cycles

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM - 5 PM Eastern time (UTC/GMT- 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-11-30
Primary Completion
2007-12-31
Completion
2007-12-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00259285 on ClinicalTrials.gov